~~<i id='41D2346EDD'><strike id='41D2346EDD'><tt id='41D2346EDD'><pre id='41D2346EDD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：knowledge 2025-09-06 03:54:35 - browse：84

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How I helped Pfizer think through the ethics of Viagra

explore

leisure time

explore

leisure time

focus

9:49AmandaZurawski,whodevelopedsepsisandnearlydiedafterbeingrefusedanabortionwhenherwaterbrokeat18we

WSS

Obamacare plans could cover weight loss drugs

FDA warns medical device makers about rise in fabricated data

New CMS data security rules will hurt Medicare, Medicaid research

Obamacare plans could cover weight loss drugs

As AI regulations shape up, health tech startups beg for clarity

'Null' research findings aren't empty of meaning. Let's publish them

leisure time

leisure time

explore

Medical leaders decry Supreme Court decision on affirmative action

WATCH: Why do our ears pop?

Hepatitis C has a cure — but many Americans still lack access to it

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Novavax promises a turnaround & Lilly roils the obesity market

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Medicare proposal to cover medical devices draws a mixed reaction

Group behind ProMed defends move to subscription

At least 13 dead in Texas as scorching temps continue

Physicians aren't 'burning out.' They're suffering from moral injury

explore

In 'major milestone,' FDA approves first cell therapy for solid tumors

FDA approves Sage Therapeutics’ rapid

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Physicians aren't 'burning out.' They're suffering from moral injury

Surprise medical billing ban raises prices elsewhere

Researchers tackle phage therapy hurdles for wider adoption

leisure time

explore

leisure time

focus